Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II weekly ABI-007 vs tri-weekly docetaxel in metastatic breast cancer
jRCT2080220890Phase 2
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of nab-paclitaxel in breast cancer (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
nab-paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080220890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220890.